ArticleBMC immunology2026
Downregulated miR-1290 serves as a diagnostic and prognostic biomarker in sepsis and protects against inflammatory injury by targeting TAOK1.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) are key regulators and potential biomarkers for early diagnosis and prognosis of sepsis. To investigate the diagnostic and prognostic value, and molecular mechanism of miR-1290 in sepsis.
methodsEnrollment comprised 127 healthy controls and 133 patients with sepsis. RT‑qPCR measured serum miR-1290 and TAO Kinase 1 (TAOK1) levels. ROC curve and Logistic regression assessed diagnostic efficacy and risk prediction of miR-1290 for sepsis. Kaplan-Meier and Cox regression evaluated its short-term prognostic value. An LPS-induced macrophage (THP-1) inflammation model was established to examine the effects of miR-1290 on cell viability (CCK-8), inflammatory cytokines TNF-α, IL-6, and IL-1β (ELISA), and macrophage polarization markers (RT-qPCR). Bioinformatic prediction and dual-luciferase reporter verified the interaction between miR-1290 and TAOK1, and rescue experiments were conducted to determine that TAOK1 reverses the biological functions of miR-1290.
resultsmiR-1290 was downregulated in patients with sepsis and showed high diagnostic value. Its expression level was negatively correlated with both SOFA and APACHE II scores, and demonstrated good predictive performance for short-term mortality. In the LPS-induced macrophage model, overexpression of miR-1290 suppressed TAOK1 expression, elevated cell viability, suppressed the secretion of TNF-α, IL-6, and IL-1β, inhibited M1 polarization (downregulation of iNOS and CD86), and enhanced M2 polarization (upregulation of CD206 and Arg-1). Moreover, TAOK1 overexpression reversed the anti-inflammatory and protective effects of miR-1290.
conclusionsDownregulated miR-1290 shows potential as both a diagnostic and prognostic indicator in sepsis. It may exert a protective effect on macrophages by targeting TAOK1, thereby inhibiting disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.